BPH Energy Limited, a subsidiary of BioPharmica Limited, is an Australian company focusing on biomedical research and oil and gas exploration. The company is developing a device called Brain Anaesthesia Response (BAR) Monitor, which measures a patient's brain electrical activity during surgery to determine their response to drugs. Additionally, BPH Energy is working on the HLS5 Tumour Suppress Gene, a genetic marker for early cancer detection. The company also holds 100% interest in RL1 oil and gas assets in the Bonaparte basin in northern Australia and an 85% interest in petroleum exploration permit 11 offshore in the Sydney basin. BPH Energy is also involved in the medicinal cannabis business. The company was founded in 2001 and is headquartered in North Perth, Australia.